# Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

> **NCT01492881** · PHASE2 · WITHDRAWN · sponsor: **UNC Lineberger Comprehensive Cancer Center**

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Vorinostat
- **DRUG:** Bortezomib
- **DRUG:** pegylated liposomal doxorubicin

## Key facts

- **NCT ID:** NCT01492881
- **Lead sponsor:** UNC Lineberger Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2012-04
- **Primary completion:** 2015-01
- **Final completion:** 2017-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Doxil is currently unavailable
- **Last updated:** 2012-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01492881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01492881, "Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT01492881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*